Cytokinetics, Incorporated (CYTK): Price and Financial Metrics
CYTK Price/Volume Stats
Current price | $70.48 | 52-week high | $110.25 |
Prev. close | $71.41 | 52-week low | $25.98 |
Day low | $69.96 | Volume | 1,065,420 |
Day high | $71.86 | Avg. volume | 3,497,044 |
50-day MA | $74.33 | Dividend yield | N/A |
200-day MA | $47.75 | Market Cap | 7.26B |
CYTK Stock Price Chart Interactive Chart >
CYTK POWR Grades
- Growth is the dimension where CYTK ranks best; there it ranks ahead of 56.32% of US stocks.
- The strongest trend for CYTK is in Stability, which has been heading down over the past 26 weeks.
- CYTK ranks lowest in Stability; there it ranks in the 4th percentile.
CYTK Stock Summary
- With a price/sales ratio of 1,087.06, CYTOKINETICS INC has a higher such ratio than 99.35% of stocks in our set.
- CYTK's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 4.47% of US stocks.
- Revenue growth over the past 12 months for CYTOKINETICS INC comes in at -94.73%, a number that bests merely 1.17% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to CYTOKINETICS INC, a group of peers worth examining would be FULC, DCPH, ADVM, CBAY, and NVAX.
- Visit CYTK's SEC page to see the company's official filings. To visit the company's web site, go to www.cytokinetics.com.
CYTK Valuation Summary
- In comparison to the median Healthcare stock, CYTK's price/earnings ratio is 153.17% lower, now standing at -15.5.
- Over the past 239 months, CYTK's EV/EBIT ratio has gone down 4.1.
Below are key valuation metrics over time for CYTK.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
CYTK | 2023-12-29 | 1047.5 | -18.7 | -15.5 | -17.7 |
CYTK | 2023-12-28 | 1044.4 | -18.6 | -15.5 | -17.7 |
CYTK | 2023-12-27 | 1046.9 | -18.6 | -15.5 | -17.7 |
CYTK | 2023-12-26 | 573.5 | -10.2 | -8.5 | -10.3 |
CYTK | 2023-12-22 | 559.6 | -10.0 | -8.3 | -10.1 |
CYTK | 2023-12-21 | 562.4 | -10.0 | -8.3 | -10.1 |
CYTK Growth Metrics
- The 3 year cash and equivalents growth rate now stands at 192.88%.
- Its 4 year net cashflow from operations growth rate is now at -380.62%.
- Its 3 year net cashflow from operations growth rate is now at -42.21%.
The table below shows CYTK's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 148.231 | -246.063 | -282.145 |
2022-06-30 | 151.153 | -200.793 | -215.921 |
2022-03-31 | 65.028 | -139.814 | -257.655 |
2021-12-31 | 70.428 | -142.522 | -215.314 |
2021-09-30 | 21.55 | -45.635 | -228.674 |
2021-06-30 | 57.801 | 7.502 | -155.763 |
CYTK's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CYTK has a Quality Grade of C, ranking ahead of 30.43% of graded US stocks.
- CYTK's asset turnover comes in at 0.108 -- ranking 258th of 682 Pharmaceutical Products stocks.
- VRTX, INBP, and MBIO are the stocks whose asset turnover ratios are most correlated with CYTK.
The table below shows CYTK's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.108 | 1 | -0.236 |
2021-03-31 | 0.129 | 1 | -0.244 |
2020-12-31 | 0.149 | 1 | -0.286 |
2020-09-30 | 0.173 | 1 | -0.292 |
2020-06-30 | 0.077 | 1 | -0.445 |
2020-03-31 | 0.095 | 1 | -0.461 |
CYTK Price Target
For more insight on analysts targets of CYTK, see our CYTK price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $44.80 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Cytokinetics, Incorporated (CYTK) Company Bio
Cytokinetics, Incorporated, a clinical stage biopharmaceutical company, focuses on the discovery and development of novel small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. The company was founded in 1997 and is based in South San Francisco, California.
Latest CYTK News From Around the Web
Below are the latest news stories about CYTOKINETICS INC that investors may wish to consider to help them evaluate CYTK as an investment opportunity.
Cytokinetics Stock Jumps To Higher RS Level; Shoots Up On Heart Drug StudyOn Thursday, Cytokinetics cleared a key performance benchmark, with its Relative Strength (RS) Rating entering into the 90-plus percentile with an improvement to 99, an increase from 89 the day before. The clinical-stage biotech company shot up 83% on Wednesday after announcing positive results from a Phase 3 study of its experimental drug to treat heart disease. The drug, Aficamten, which treats symptomatic obstructive hypertrophic cardiomyopathy (HCM) is a contender to challenge Bristol Myer Squibb's Camzyos drug. |
Cytokinetics (CYTK) Up 83% as Cardiomyopathy Drug Meets GoalsCytokinetics (CYTK) reports positive results from its pivotal late-stage study of aficamten in symptomatic obstructive hypertrophic cardiomyopathy patients. The stock rallies 83% in response. |
Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study DataBristol Myers (BMY) and Cytokinetics (CYTK) are in the news on acquisition announcements and study updates, respectively. |
Company News for Dec 28, 2023Companies In The Article Are:CYTK,TSLA, NYT, MSFT, IOVA |
Stocks Static As Post-Holiday Doldrums HitStocks are struggling for direction today, as the post-holiday doldrums take full effect. |
CYTK Price Returns
1-mo | -12.98% |
3-mo | -15.58% |
6-mo | 139.24% |
1-year | 99.94% |
3-year | 210.62% |
5-year | 771.20% |
YTD | -15.58% |
2023 | 82.21% |
2022 | 0.53% |
2021 | 119.35% |
2020 | 95.85% |
2019 | 67.88% |
Continue Researching CYTK
Want to see what other sources are saying about Cytokinetics Inc's financials and stock price? Try the links below:Cytokinetics Inc (CYTK) Stock Price | Nasdaq
Cytokinetics Inc (CYTK) Stock Quote, History and News - Yahoo Finance
Cytokinetics Inc (CYTK) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...